The best documented differences are found between Serous Ovarian Carcinomas bearing a germline BRCA1 mutation, which in most cases show increased sensitivity to platinum-based chemotherapy, and sporadic SOC devoid of BRCA1 mutations, which respond poorly [7, 8]. This evidence concerns the gene BRCA1 and ovarian serous carcinoma.